Systemic therapy: Selection of patients endocrine therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

About two-thirds of all breast tumours are hormone receptor-positive, and therefore expectedly hormone-sensitive. The proportion of ER-positive breast cancers is even higher among early breast cancers. The rationale the currently applied endocrine manipulations is oestrogen deprivation, either by competitive blockade of the hormone at the level of its receptor or by inhibition of its synthesis. The automatic administration of endocrine agents to all patients with hormone receptor-positive breast cancer would mean overtreatment, and would cause unnecessary morbidity to many patients. The adverse effects of endocrine therapies include gynaecologic toxicity and sexual dysfunction, osteoporosis, arthralgia, effects on the nervous system and cognitive dysfunction, thus deteriorating health-related quality of life (HRQOL). An effort should be made to balance the issues relating to the risk of relapse and the extent of hormone sensitivity, and hence the expected benefit of therapy, together with the risks accompanying the endocrine therapy.

Original languageEnglish
Title of host publicationBreast Cancer, a Heterogeneous Disease Entity: The Very Early Stages
PublisherSpringer Netherlands
Pages283-304
Number of pages22
ISBN (Print)9789400704886
DOIs
Publication statusPublished - 2011

Fingerprint

Patient Selection
Hormones
Breast Neoplasms
Therapeutics
Arthralgia
Nervous System
Osteoporosis
Estrogens
Quality of Life
Morbidity
Recurrence

Keywords

  • Adverse effects
  • Hormone sensitivity
  • Hormone therapy
  • Oestrogen deprivation
  • Overtreatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kahán, Z. (2011). Systemic therapy: Selection of patients endocrine therapy. In Breast Cancer, a Heterogeneous Disease Entity: The Very Early Stages (pp. 283-304). Springer Netherlands. https://doi.org/10.1007/978-94-007-0489-3_12

Systemic therapy : Selection of patients endocrine therapy. / Kahán, Z.

Breast Cancer, a Heterogeneous Disease Entity: The Very Early Stages. Springer Netherlands, 2011. p. 283-304.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kahán, Z 2011, Systemic therapy: Selection of patients endocrine therapy. in Breast Cancer, a Heterogeneous Disease Entity: The Very Early Stages. Springer Netherlands, pp. 283-304. https://doi.org/10.1007/978-94-007-0489-3_12
Kahán Z. Systemic therapy: Selection of patients endocrine therapy. In Breast Cancer, a Heterogeneous Disease Entity: The Very Early Stages. Springer Netherlands. 2011. p. 283-304 https://doi.org/10.1007/978-94-007-0489-3_12
Kahán, Z. / Systemic therapy : Selection of patients endocrine therapy. Breast Cancer, a Heterogeneous Disease Entity: The Very Early Stages. Springer Netherlands, 2011. pp. 283-304
@inbook{bbd60b03be8c42b9bf75fdd8d1740835,
title = "Systemic therapy: Selection of patients endocrine therapy",
abstract = "About two-thirds of all breast tumours are hormone receptor-positive, and therefore expectedly hormone-sensitive. The proportion of ER-positive breast cancers is even higher among early breast cancers. The rationale the currently applied endocrine manipulations is oestrogen deprivation, either by competitive blockade of the hormone at the level of its receptor or by inhibition of its synthesis. The automatic administration of endocrine agents to all patients with hormone receptor-positive breast cancer would mean overtreatment, and would cause unnecessary morbidity to many patients. The adverse effects of endocrine therapies include gynaecologic toxicity and sexual dysfunction, osteoporosis, arthralgia, effects on the nervous system and cognitive dysfunction, thus deteriorating health-related quality of life (HRQOL). An effort should be made to balance the issues relating to the risk of relapse and the extent of hormone sensitivity, and hence the expected benefit of therapy, together with the risks accompanying the endocrine therapy.",
keywords = "Adverse effects, Hormone sensitivity, Hormone therapy, Oestrogen deprivation, Overtreatment",
author = "Z. Kah{\'a}n",
year = "2011",
doi = "10.1007/978-94-007-0489-3_12",
language = "English",
isbn = "9789400704886",
pages = "283--304",
booktitle = "Breast Cancer, a Heterogeneous Disease Entity: The Very Early Stages",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Systemic therapy

T2 - Selection of patients endocrine therapy

AU - Kahán, Z.

PY - 2011

Y1 - 2011

N2 - About two-thirds of all breast tumours are hormone receptor-positive, and therefore expectedly hormone-sensitive. The proportion of ER-positive breast cancers is even higher among early breast cancers. The rationale the currently applied endocrine manipulations is oestrogen deprivation, either by competitive blockade of the hormone at the level of its receptor or by inhibition of its synthesis. The automatic administration of endocrine agents to all patients with hormone receptor-positive breast cancer would mean overtreatment, and would cause unnecessary morbidity to many patients. The adverse effects of endocrine therapies include gynaecologic toxicity and sexual dysfunction, osteoporosis, arthralgia, effects on the nervous system and cognitive dysfunction, thus deteriorating health-related quality of life (HRQOL). An effort should be made to balance the issues relating to the risk of relapse and the extent of hormone sensitivity, and hence the expected benefit of therapy, together with the risks accompanying the endocrine therapy.

AB - About two-thirds of all breast tumours are hormone receptor-positive, and therefore expectedly hormone-sensitive. The proportion of ER-positive breast cancers is even higher among early breast cancers. The rationale the currently applied endocrine manipulations is oestrogen deprivation, either by competitive blockade of the hormone at the level of its receptor or by inhibition of its synthesis. The automatic administration of endocrine agents to all patients with hormone receptor-positive breast cancer would mean overtreatment, and would cause unnecessary morbidity to many patients. The adverse effects of endocrine therapies include gynaecologic toxicity and sexual dysfunction, osteoporosis, arthralgia, effects on the nervous system and cognitive dysfunction, thus deteriorating health-related quality of life (HRQOL). An effort should be made to balance the issues relating to the risk of relapse and the extent of hormone sensitivity, and hence the expected benefit of therapy, together with the risks accompanying the endocrine therapy.

KW - Adverse effects

KW - Hormone sensitivity

KW - Hormone therapy

KW - Oestrogen deprivation

KW - Overtreatment

UR - http://www.scopus.com/inward/record.url?scp=84900292902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900292902&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-0489-3_12

DO - 10.1007/978-94-007-0489-3_12

M3 - Chapter

AN - SCOPUS:84900292902

SN - 9789400704886

SP - 283

EP - 304

BT - Breast Cancer, a Heterogeneous Disease Entity: The Very Early Stages

PB - Springer Netherlands

ER -